Editas med stock.

Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …Hillevax Inc. 12.75. +0.65. +5.37%. Get Editas Medicine Inc (EDIT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Apr 6, 2023 · Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a ... Click on the text tab and select a style of your choice. Change the size and color of the selected font to make it fit your design. You can also add some fun elements to make your 2048 x 1152 pixels YouTube channel art-pop. Select the ‘ Objects ’ bar and put in elements that fit the theme of your YouTube banner.

Aug 7, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...

Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...

Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, ... Editas Medicine Inc (NASDAQ:EDIT) Real-Time Quotes. 10.68. BATS BZX Real-Time Price. As of 3:23pm ETNov 24, 2023 · Editas Medicine Announces Offering of Common Stock CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of sha... CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 12.83% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $8.66 and a low of $6.33. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Jan 13, 2022 · Shares of Editas Medicine ( EDIT -2.58%) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. The company presented at the ...

Finance. Industry. Market

As of March 31, 2023, Editas Medicine had $401.8 million in cash, cash equivalents, and marketable securities, which is expected to fund their operating expenses and capital expenditures until 2025.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Detailed statistics for Editas Medicine, Inc. (EDIT) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for Editas Medicine, Inc. (EDIT) ... Editas Medicine, Inc. (EDIT) NASDAQ: EDIT · IEX Real-Time Price · USD. Add to Watchlist 7.67-0.20 (-2.54%) Nov 10, 2023, 4:00 PM EST ...Shares of Editas Medicine ( EDIT 2.28%) were up 13.9% this week as of the market close on Thursday. Most of this big gain came after a key announcement from the company on Wednesday about its ...1. Editas Medicine Editas Medicine is a biotech company that focuses on gene-editing therapies. Like many of its peers in this niche, Editas Medicine currently has no approved products and isn't ...Editas Medicine (NASDAQ: EDIT), a genome-editing company, has seen a significant 20% surge in its stock, marking its largest increase over two years.This comes despite a 4.9% dip year-to-date and ...CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic update, including portfolio reprioritization and research and development realignment. The Company’s R&D efforts will narrow, focusing on hemoglobinopathies …May 5, 2023 · As of March 31, 2023, Editas Medicine had $401.8 million in cash, cash equivalents, and marketable securities, which is expected to fund their operating expenses and capital expenditures until 2025.

View Georgia Giannoukos’ profile on LinkedIn, the world’s largest professional community. Georgia has 1 job listed on their profile. See the complete profile on LinkedIn and discover Georgia ...Nov 24, 2023 · Editas Medicine Announces Offering of Common Stock CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of sha... Shares of Editas Medicine ( EDIT 3.07%), a clinical-stage biotech company, fell by 15.5% in November, according to data from S&P Global Intelligence. The stock closed October at $12.55 a share ...Feb 3, 2023 · With shares down by 60% in the last three years, Editas Medicine (EDIT-0.75%) investors are experiencing a bumpy ride despite the company's impeccable gene-editing credentials. But for a biotech ... Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.

Aug 23, 2023 · That's why companies such as Editas Medicine ( EDIT 0.86%) and Intellia Therapeutics ( NTLA 2.54%) are down massively over the trailing 12-month period. However, Wall Street expects both to bounce ... Editas Medicine, Inc. (EDIT) Stock Price, Quote, News & Analysis EDIT Editas Medicine, Inc. Stock Price & Overview 38.49K followers $10.53 -0.08 ( -0.75%) 4:00 PM 11/30/23 NASDAQ |...

Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...The analyst also gave the stock a price target of $20. Editas Medicine's share price as of the closing of business day yesterday was $40.98. And even after today's sell-off, Editas Medicine stock ...As of June 1, 2023, Editas Medicine Inc’s stock price is $9.55, which is up 4.03% from its previous closing price. At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics ...Editas Medicine works with two distinct CRISPR nucleases: Cas9 and Cas12a (also known as Cpf1). Both nucleases have distinct gene editing and targeting capabilities. Using these two nucleases, we can access a broad range of genetic mutations and develop targeted and durable gene edited medicines. We are researching and developing two types of ... According to 5 analyst offering 12-month price targets in the last 3 months, Editas Medicine has an average price target of $15.4 with a high of $19.00 and a low of $12.00.Nov 3, 2023 · Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago.

The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Like many other stocks, Editas Medicine was crushed over the last 18 months. Since the middle of 2021, EDIT plummeted from a high of about $72.50 to $8.43.

Penn Med Radnor is a premier healthcare facility that has been providing exceptional cardiovascular care to its patients for many years. One of the most significant advancements in cardiovascular care at Penn Med Radnor is the use of advanc...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 12.83% so far this month. During the month of April, Editas Medicine Inc’s stock price has reached a high of $8.66 and a low of $6.33. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Shares of Editas Medicine ( EDIT 3.66%) were jumping 7% as of 11:53 a.m. EDT on Monday after rising as much as 20.2% earlier in the day. The gain came after another CRISPR-focused biotech ...Discover historical prices for EDIT stock on Yahoo Finance. View daily, weekly or monthly format back to when Editas Medicine, Inc. stock was issued.May 8, 2023 · Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ... Here are three solid ways to trade the gene-editing boom. Editas Medicine ( EDIT ): EDIT has a major catalyst on Dec. 11 to watch for. ARK Genomic Revolution ETF …The latest price target for Editas Medicine ( NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. The analyst firm set a price target for 11.00 expecting EDIT to rise to within ...Stock Price Forecast. According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an increase of 31.81%. The lowest target is $7.00 and the highest is $36. On average, analysts rate EDIT stock stock as a buy.Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at ...Apr 3, 2023 · Editas Medicine (EDIT 0.86%) sits at the bleeding edge of biotech's hottest field, gene editing to treat inherited diseases. The company has shifted its focus to a product it is testing for severe ...

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... EDIT - Editas …Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Buying or selling a stock that's not traded in your local currency? Don't let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares ...Instagram:https://instagram. 7 year treasury ratesjim priceprivate dental insurance arizona2009 bicentennial lincoln penny Editas Medicine, Inc. - Hold. Zacks' proprietary data indicates that Editas Medicine, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the EDIT shares relative ...Funding could be an issue. Editas Medicine ended the first quarter with $401.8 million in cash and equivalents, down from the $437.4 million it had at the end of 2022. In its quarterly update, the ... willton investment managementhealth and dental insurance south carolina View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. worrior trading Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19.Finance. Industry. MarketThe past month has been a great one for Editas Medicine (EDIT 0.86%), but the stock is still down about 89% from the peak it reached in 2021. Wall Street analysts who follow the biotechnology ...